The pharmaceutical industry continues to grapple with quality control issues. Traditional inspection methods are failing to meet the demands of modern production, with high-profile contamination incidents like stainless steel particles in Moderna vaccines exposing critical vulnerabilities. Manual inspection remains prone to human error, whilst conventional automated systems can only detect what they’ve been programmed to find. As regulatory scrutiny intensifies and production complexity increases, manufacturers need a solution. AI automated technology represents a sophisticated evolution in visual inspection that addresses fundamental limitations of both manual and traditional automated approaches. Promising to transform pharmaceutical quality assurance, artificial intelligence-driven inspection offers the capability to achieve zero-defect production whilst maintaining commercial viability.